<DOC>
	<DOCNO>NCT02878772</DOCNO>
	<brief_summary>Immunity inflammation play critical role pathogenesis acute ischemic stroke . Therefore , immune intervention , new therapeutic strategy , worthy exploration . Here , investigator test inflammation modulator , vinpocetine , effect outcome stroke . For multi-center study , investigator recruit 60 patient anterior cerebral circulation occlusion onset stroke exceed 4.5 hour last less 48 hour . These patient , randomly division two group , receive either standard management alone ( control ) standard management plus vinpocetine ( 30 mg per day intravenously 14 consecutive day , Gedeon Richter Plc. , Hungary ) .</brief_summary>
	<brief_title>Vinpocetine Inhibits NF-ÎºB-dependent Inflammation Acute Ischemic Stroke Patients</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Vinpocetine</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<criteria>&gt; 18 year age Anteriorcirculation ischemic stroke : All patient symptoms focal neurological deficit simultaneous radiological evidence ( magnetic resonance imaging , MRI ) ischemic brain lesion measurable neurological deficit ( NIHSS &gt; 5 ) interval symptom onset admission 4.5 hour less 48 hour . That , patient recruit beyond 4.5 hour symptom onset , therefore , past accept timewindow thrombolytic therapy hemorrhagic stroke severe hemorrhage organ diseases central nervous system ( CNS ) diabetes mellitus tumor hematological systemic disease infection acute ischemic stroke concomitant use antineoplastic immune modulate therapy contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>